Get started
BaxterBaxterBaxter

Baxter

No trades
See on Supercharts
Overview News
Ideas
Discussions Seasonals

BAX trade ideas

Baxter International Inc. (BAX) | Chart & Forecast SummaryKey Indicators on Trade Set Up in General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Active Sessions on Relevant Range & Elemented Probabilities; * Asian(Ranging) - London(Upwards) - NYC(Downwards) * Weekend Crypto Session # Trend | Time Frame Conductive | Weekly Time Frame - General Trend - Measurement on Session * Support & Resistance * Trade Area | Focus & Motion Ahead # Position & Risk Reward | Daily Time Frame - Measurement on Session * Retracement | 0.5 & 0.618 * Extension | 0.786 & 1 Conclusion | Trade Plan Execution & Risk Management on Demand; Overall Consensus | Buy
CAPITALCOM:BAXLong
by P-Ment4U
Baxter International | BAX | Long at $35.00Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend. Interest rates being lowered soon will help these projections. From a technical analysis perspective, my selected simple moving average is working its way down to recapture the price for a likely reversal in the next year or two (unless company fundamentals change). The recent low in June 2024 was higher than the previous low in October 2023 (higher lows) indicating a high chance of future price improvement - but nothing is guaranteed. At $35.00, it is currently in a personal buy zone. Target #1 - $40.00 Target #2 - $48.00 Target #3 - $51.50 Target #4 - $65.00 Target #5 - $77.00 (very long-term...)
NYSE:BAXLong
by NicksAnalysis
Decent entry?Decent long term buy point? Here is a stock that has come back down to the support line it has used for the last 20 years. It was this line that was able to get it passed the resistance line from late 2002 to late 2012. After it broke the high resistance in 2012 it tested it and held as new support. It more than doubled after that point. This puts us at Intersecting line of 20 years of support, and the last major resistance line it has broken through and tested once already and held. Making this a potential spot for some solid support for a long term buy entry. Time will tell.
NYSE:BAXLong
by axlmayhem87
BAX is ready to make new peak. Not Investing Advice!1) In Technical Analysis Divergence(Negative = Sell, Positive = Buy) is very important and i found Positive Divergence on indicators such as CCI, RSI, Momentum. Price bottoms are decreasing but indicator bottoms are increasing it is description of Positive Divergence. 2) On RSI indicator, it is oversold area and i found important support horizontal lines on RSI indicator and they are shown on chart which are blue. Important Horizontal Support Lines: 30.69 / 29.15 / 26.09 / 23.64 3) I drew support and resistance lines on Momentum indicator i mean it is channel. It is broken resistance line but we have to wait at the end of this month's closing line of Momentum. I applied SMA(8 period) on Momentum and it has already been cut above by Momentum. 4) CCI has not cut above its moving average so it is not buy sign. Also i applied WMA(14 period) on CCI indicator. 5) On DMI ADX(Red one) cut above -DI(Orange one) in March. It was buy sign and it is still valid for now.
NYSE:BAX
by Emirhanhmc
BAX - Trend ReversionTrade Theme Trend Reversion Sector/Stock BAX Trend Y/Y Propulsion No Vscore Yes Vprofile Yes RAF Not at Extreme Darvas Yes Darvas 3.0 Yes Entry 40.2 Minor Low Breakout. Look for improvement on breakout pullback. Profit/Breakeven 39.2 50% Fib retracement and Volume resistance. Stop Loss 25% Stop Loss Option 19May23 40 Puts BAX had been in a solid R/R downtrend and pulled back to the WAVE last week. Trend has started to become sideways, but the past trend is very strong. I have solid RAF/Vscore/Vprofile signals and signs that momentum will resume. Bot 2 19May23 40Puts @ $2.00 today on the break below 40.20.
NYSE:BAXShort
by TradingBandito06
BAX | Catch the Falling Knife | LONGBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
NYSE:BAXLong
by DivergenceSeeker
3
Baxter Inc. (BAX) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 41.98 USD. According to experts, your stop-loss order should be placed at 37.35 USD if you decide to enter this position. U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
Pull Back FishingThis usd to be a strong medical supply company but appears something had gone awry. Looks like a pennant but the bole is Down. Either way this pattern in neutral until broken. Recent earnings miss. No recommendation. EPS (FWD) 2.85 PE (FWD) 14.26 Div Rate (FWD) $1.16 Yield (FWD) 2.85% Short Interest 0.98% Market Cap $20.54B Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.
NYSE:BAX
by lauralea
Baxter (BAX) bullish scenario:The technical figure Pennant can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The company had 2017 sales of $10.6 billion, across two businesses: BioScience and Medical Products. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage kidney disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis. The Pennant broke through the resistance line on 28/12/2022. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 6 days towards 53.63 USD. Your stop-loss order, according to experts, should be placed at 49.17 USD if you decide to enter this position. Baxter International Inc. has announced that it will pay a dividend of $0.29 per share on the 3rd of January. This means the dividend yield will be fairly typical at 2.1%. Analysts expect a massive rise in earnings per share in the next year. If the dividend extends its recent trend, estimates say the dividend could reach 17%, which we would be comfortable to see continuing. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
Baxter International shares look extremely cheapTarget horizon - 2 months. Target - 84 USD. Profit/risk ratio - 3.43 The price is approaching the upper boundary of the downtrend, and if it breaks it is likely to go to the support line around 85 USD. Baxter International is an American medical device manufacturer specializing in high-tech dialysis machines and other medical devices and supplies. Thousands of patients prolong their lives thanks to Baxter equipment, which is used in more than 100 countries. After a major downturn, the company's stock looks extremely cheap, and from an operational standpoint, there's no reason to worry about Baxter's business.
NYSE:BAXLong
by SiriusBH
Baxter International USA Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision. #debadipb #profitsolutions
NYSE:BAX
by Sunstorminvest